Latest Share Chat

REMOVE ADS

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,913.00 -25.00 (-1.29%)

Bid:

1,917.00

Ask:

1,918.00

Spread: 1.00 (0.052%)

Market Cap: £76.72b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Glaxosmithkline News

GSK wins US FDA approval of combo with blood cancer drug Blenrep

(Alliance News) - GSK PLC said Thursday its drug Blenrep has been approved by the US Food & Drug Administration for the treatment of adults with relap...

LONDON BRIEFING: UK retail sales rise; NatWest lifts 2025 guidance

(Alliance News) - NatWest Group upgraded its 2025 guidance after reporting a strong third-quarter profit rise, while GSK secured US approval for its m...

GSK's Blenrep receives US FDA approval

(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration had approved its Blenrep asset in combination with bortezomib...

UK earnings, trading statements calendar - next 7 days

GSK halts dementia study after trial results; moves ahead with inhaler

(Alliance News) - GSK PLC and Nasdaq-listed Alector Inc on Wednesday said they won't proceed with a study into a possible dementia treatment after tri...

GSK advances low-carbon inhaler, halts latozinemab study after mixed data

(Sharecast News) - Drugmaker GSK released two sets of trial data on Wednesday, covering its low-carbon asthma inhaler and a potential new treatment fo...

GSK reports positive updates on Shingrix and tebipenem HBr

(Alliance News) - GSK PLC on Tuesday announced a double dose of good news regarding shingles drug, Shingrix, and urinary tract infection treatment, te...

GSK reports positive trial data for oral cUTI treatment, secures EU backing for simplified shingles vaccine

(Sharecast News) - Drugmaker GSK made two key updates on Monday, with positive phase III trial results for tebipenem HBr, an investigational oral anti...